Share-based Payment Arrangement, Expense of NextCure, Inc. from 31 Mar 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NextCure, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2018 to 30 Sep 2025.
  • NextCure, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $600,000, a 61% decline year-over-year.
  • NextCure, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,069,000, a 40% decline year-over-year.
  • NextCure, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,335,000, a 23% decline from 2023.
  • NextCure, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,188,000, a 14% decline from 2022.
  • NextCure, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,508,000, a 7.6% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NextCure, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,069,000 $600,000 -$929,000 -61% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $4,998,000 $587,000 -$1,007,000 -63% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $6,005,000 $1,363,000 -$330,000 -19% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $6,335,000 $1,519,000 -$465,000 -23% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $6,800,000 $1,529,000 -$472,000 -24% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $7,272,000 $1,594,000 -$531,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $7,803,000 $1,693,000 -$385,000 -19% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $8,188,000 $1,984,000 -$342,000 -15% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $8,530,000 $2,001,000 -$311,000 -13% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $8,841,000 $2,125,000 -$117,000 -5.2% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $8,958,000 $2,078,000 -$550,000 -21% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $9,508,000 $2,326,000 -$184,000 -7.3% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $9,692,000 $2,312,000 -$171,000 -6.9% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $9,863,000 $2,242,000 -$545,000 -20% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $10,408,000 $2,628,000 +$120,000 +4.8% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $10,288,000 $2,510,000 +$166,000 +7.1% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $10,122,000 $2,483,000 +$111,000 +4.7% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $10,011,000 $2,787,000 +$600,000 +27% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $9,411,000 $2,508,000 +$1,500,000 +149% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $7,911,000 $2,344,000 +$1,777,000 +313% 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q3 2020 $6,134,000 $2,372,000 +$1,848,000 +353% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $4,286,000 $2,187,000 +$1,775,000 +431% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $2,511,000 $1,008,000 +$625,000 +163% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $1,886,000 $567,000 +$442,000 +354% 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q3 2019 $1,444,000 $524,000 +$434,000 +482% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,010,000 $412,000 +$388,000 +1617% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $622,000 $383,000 +$359,000 +1496% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $263,000 $125,000 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $90,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $24,000 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2
Q1 2018 $24,000 01 Jan 2018 31 Mar 2018 10-Q 10 Jun 2019 2019 Q1

NextCure, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,335,000 -$1,853,000 -23% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $8,188,000 -$1,320,000 -14% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $9,508,000 -$780,000 -7.6% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $10,288,000 +$2,377,000 +30% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $7,911,000 +$6,025,000 +319% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
2019 $1,886,000 +$1,623,000 +617% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
2018 $263,000 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.